|
|
|
|
A more recent version of this article appeared on January 1, 2005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 2, 2004
Revised on September 28, 2004
Accepted on October 4, 2004
Membrane Localization: Regulation by 17
-Estradiol


*Department of Biology, University Roma Tre, I-00146 Rome, Italy;
Interdepartmental Laboratory for Electron Microscopy, University Roma Tre, I-00146 Rome, Italy;
National Institute for Infectious Diseases Istituto di Ricovero e Cura a Carattere Scientifico Lazzaro Spallanzani, I-00149 Rome, Italy;
Department of Chemistry, Chemical Engineering, and Materials, University of L’Aquila, I-67100 L’Aquila, Italy; ||Department of Experimental Biology, University of Bologna, I-40126 Bologna, Italy
Monitoring Editor: Keith Yamamoto
A fraction of the nuclear estrogen receptor
(ER
) is localized to the plasma membrane region of 17
-estradiol (E2) target cells. We previously reported that ER
is a palmitoylated protein. To gain insight into the molecular mechanism of ER
residence at the plasma membrane we tested both the role of palmitoylation and the impact of E2 stimulation on ER
membrane localization. The cancer cell lines expressing transfected or endogenous human ER
(HeLa and HepG2, respectively) or the ER
nonpalmitoylable Cys447Ala mutant transfected in HeLa cells were used as experimental models. We found that palmitoylation of ER
enacts ER
association with the plasma membrane, interaction with the membrane protein caveolin-1, and nongenomic activities, including activation of signaling pathways and cell proliferation (i.e., ERK and AKT activation, cyclin D1 promoter activity, DNA synthesis). Moreover, E2 reduces both ER
palmitoylation and its interaction with caveolin-1, in a time- and dose-dependent manner. These data point to the physiological role of ER
palmitoylation in the receptor localization to the cell membrane and in the regulation of the E2-induced cell proliferation.